Navigation Links
SHAREHOLDER ALERT: Pomerantz Law Firm Announces the Filing of a Class Action against Provectus Biopharmaceuticals, Inc. and Certain Officers - PVCT
Date:7/10/2014

NEW YORK, June 27, 2014 /PRNewswire/ -- Pomerantz LLP has filed a class action lawsuit against Provectus Biopharmaceuticals, Inc. ("Provectus" or the "Company")(NYSE-MKT: PVCT) and certain of its officers.  The class action, filed in United States District Court, Middle District of Tennessee, Nashville Division, is on behalf of a class consisting of all persons or entities who purchased or otherwise acquired Provectus securities between December 17, 2013 and May 22, 2014, both dates inclusive (the "Class Period"). This class action seeks to recover damages against Defendants for alleged violations of the federal securities laws pursuant to Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder.

If you are a shareholder who purchased Provectus securities during the Class Period, you have until July 28, 2014 to ask the Court to appoint you as Lead Plaintiff for the class.  A copy of the Complaint can be obtained at www.pomerantzlaw.com.   To discuss this action, contact Robert S. Willoughby at rswilloughby@pomlaw.com or 888.476.6529 (or 888.4-POMLAW), toll free, x237. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and number of shares purchased.

Provectus is a development-stage biopharmaceutical company that focuses on developing pharmaceuticals for oncology and dermatology indications. The most important drug in the Company's pipeline is an oncology drug, PV-10, which is intended for the treatment of several life threatening cancers, including metastatic melanoma, liver cancer, and breast cancer. 

The Complaint alleges that throughout the Class Period, Defendants made materially false and misleading statements regarding the Company's business, operational and
'/>"/>

SOURCE Pomerantz LLP
Copyright©2014 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology news :

1. Acquisition of BioClinica, Inc. by JLL Partners, Inc. May Not Be in BioClinica, Inc. Shareholders Best Interests
2. Medbox Communicates with Shareholders, Comments on Pending Transition to OTC Bulletin Board, and Announces Appearance on Fox Business News Channel
3. Investigation of American Oriental Bioengineering, Inc. by Securities Lawyers at Goldfarb LLP Law Firm for Potential Shareholder Claim
4. Red alert: Body kills spontaneous blood cancers on a daily basis
5. Media alert: Society of Interventional Radiologys Annual Scientific Meeting
6. Webcast alert: Molecular Medicine Institute to give new hope to pediatric patients
7. Avery Biomedical Devices, Inc. announces the appointment of Mark E Ginsburg, M.D. to its Board of Directors
8. BrightFocus Foundation announces 55 new grantees in Alzheimers and vision research
9. Elsevier Announces the launch of open access journal: New Negatives in Plant Science
10. Institute of Physics announces 2014 award winners
11. Elsevier announces the launch of a new journal: Current Opinion in Behavioral Sciences
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/27/2015)... 2015 Profile Solutions, Inc. (OTC: PSIQ), a ... is pleased to announce that Dr Gerry Bedore ... member of its scientific advisory board. ... thought leader in technology-enhanced learning models. He was a ... published studies and books focused on online student success ...
(Date:4/14/2015)... YORK , April 14, 2015  HYPR ... IDentity Online (FIDO ® ) Alliance tm , ... specifications. FIDO members commit to share technology and ... methods that are interoperable, more secure and private, ... enable biometric identity verification that protects sensitive user ...
(Date:4/9/2015)... SAN JOSE, Calif. , April 9, 2015 /PRNewswire/ ... of human interface solutions, announced today that it will ... 2015 on Thursday, April 23, 2015, after the close ... call for analysts and investors at 2:00 p.m. PT ... information.    To participate on the live ...
Breaking Biology News(10 mins):Profile Solutions Names Medicinal Cannabis, Agriculture and Technology Expert Dr. Gerry Bedore to its Scientific Advisory Board 2Profile Solutions Names Medicinal Cannabis, Agriculture and Technology Expert Dr. Gerry Bedore to its Scientific Advisory Board 3Profile Solutions Names Medicinal Cannabis, Agriculture and Technology Expert Dr. Gerry Bedore to its Scientific Advisory Board 4HYPR Corp. Joins the FIDO Alliance 2HYPR Corp. Joins the FIDO Alliance 3Synaptics to Report Third Quarter Results on April 23 2
... that the effects of prion disease could be reversed ... findings support developing early treatments that aim to reduce ... with prion disease. Also, they said that their findings ... way: by analyzing their cognitive effects in prion-infected mice. ...
... autopsy data provide the strongest evidence yet that sudden infant ... a concrete biological basis. In the November 1 issue of ... brainstem ?a part of the brain that regulates breathing, blood ... SIDS. , SIDS is the leading cause of death ...
... Jude Children's Research Hospital have demonstrated in a mouse model ... that not only greatly reduces the size of the tumor, ... standard chemotherapy. The treatment also appears to be suitable for ... is simple enough for widespread use even in countries with ...
Cached Biology News:Prion disease treatable if caught early 2A potential biological cause for sudden infant death syndrome 2A potential biological cause for sudden infant death syndrome 3St. Jude announces breakthrough in eye cancer treatment 2St. Jude announces breakthrough in eye cancer treatment 3St. Jude announces breakthrough in eye cancer treatment 4
(Date:4/27/2015)... 2015  For about a century, a known ... to utilize and catabolize glucose at a high ... called the ,Warburg phenomenon", that is an increased ... presence, leading to enhanced lactate generation. Even under ... glucose fermentation. A variety of such abnormalities have ...
(Date:4/27/2015)... /PRNewswire/ - iCo Therapeutics ("iCo" or "the Company") (TSX-V: ... the year ended December 31, 2014. Amounts, unless ... presented under International Financial Reporting Standards ("IFRS"). ... not provide the outcome management and investors had ... iCo Therapeutics", said Andrew Rae , President ...
(Date:4/27/2015)... HEIDELBERG , Alemania, April 27, 2015 /PRNewswire/ ... para un nuevo receptor utilizando tecnología de descubrimiento de ... cubierta en el tratamiento de millones de pacientes con ... hoy que ha recibido una patente en Europa titulada ... descubrimiento de Molecular Health de que EPHB4 es un ...
(Date:4/27/2015)... Dr. Robert Hanzlik, whose groundbreaking research into ... for advancing the creation of safer pharmaceuticals, will be ... , the second-largest private, nonprofit university in California. , ... at the University of Kansas School of Pharmacy who ... 5 p.m. and takes place at National University’s Torrey ...
Breaking Biology Technology:Study Indicates Cancer Cells Alter Glucose Metabolism to Enhance Energy Production and Cell Growth 2iCo Therapeutics Announces Year End 2014 Financial Results 2iCo Therapeutics Announces Year End 2014 Financial Results 3iCo Therapeutics Announces Year End 2014 Financial Results 4Molecular Health obtiene la patente para un nuevo receptor 2Molecular Health obtiene la patente para un nuevo receptor 3Dr. Robert Hanzlik Discusses Pharmaceutical Testing Models at Event Hosted by National University 2Dr. Robert Hanzlik Discusses Pharmaceutical Testing Models at Event Hosted by National University 3
... , , PRINCETON, N.J., July 24 ... companies from around the world who gather at InformexUSA 2010 will ... past, allowing them to connect more precisely with others in their ... The show opens February 16, 2010 in San Francisco, with a ...
... , SILVER SPRING, Md., July 24 ... that it will release its 2009 second quarter financial results ... , United Therapeutics Corporation will host ... a.m. Eastern Time. The teleconference is accessible by dialing ...
... ... offers Fetal Bovine Serum (FBS) originating from abattoirs located in the US, ... treatments such as heat inactivation, dialysis, or gamma irradiation are available as ... FBS for embryonic stem cell research. Each FBS order includes a ...
Cached Biology Technology:Informex Rebrands Into Separate Pharmaceutical and Specialty Chemical Segments to Better Serve Exhibitors and Attendees 2Informex Rebrands Into Separate Pharmaceutical and Specialty Chemical Segments to Better Serve Exhibitors and Attendees 3Spectrum Announces Fetal Bovine Serum Product Line 2
... I catalyzes the template-directed polymerization of nucleotides ... DNA Polymerase I possesses a 3?5 exonuclease ... error rate during DNA replication, and also ... the enzyme to replace nucleotides in the ...
... Exonuclease-free Klenow Fragment is a genetically engineered Klenow ... activity has been removed, leaving only the 5 ... activity makes Exo- Klenow Fragment the enzyme of ... probes by the random primed method, and for ...
Request Info...
DNA polymerase I, large fragment...
Biology Products: